

AGENDA

***Uniform Formulary Beneficiary Advisory Panel
7 January 2016 @ 0900 AM***

***Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004***

- **Administrative Meeting (BAP members only @ 7:45 AM-9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division Formulary Management Branch will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations for the following drug classes during the November 2015 meeting:

- ***Designated Newly Approved Drugs***
 - ***Alzheimer's Drugs—Memantine Extended Release (Namenda XR) and Memantine Extended Release/Donepezil (Namzaric)***
- ***Drug Class Reviews:***
 - ***Attention Deficit Hyperactivity Disorder (ADHD): Stimulants***
 - ***Antirheumatics: Injectable Methotrexate***
 - ***Acne Drugs: Oral Isotretinoin***
 - ***Gastrointestinal (GI)-2 Miscellaneous Drugs***
- ***Utilization Management Issues***
 - ***Prior Authorization Criteria***
 - ***Targeted Immunomodulatory Biologics (TIBs)—Adalimumab Injection (Humira)***
 - ***Anti-Malarial Drugs—Mefloquine (Lariam, generic)***
 - ***Hepatitis C Virus (HCV) Drugs—Direct Acting Agents***
 - ***Female Hyposexual Desire Disorder—Flibanserin (Addyi)***
 - ***Basal Insulins—Insulin Glargine 300 U/mL (Toujeo)***

- *Chronic Heart Failure Drugs—Ivabradine (Corlanor)*

- *Innovator Drugs*

- *Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors—Evolocumab (Repatha) Injection*
- *Oral Oncologic Drugs—Trifluridine/Tipiracil (Lonsurf)*
- *Non-Insulin Diabetes Drugs: Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors—Empagliflozin/Metformin Immediate Release (Synjardy)*

- *NDAA 2007 Section 703 Actions*

- *Panel Discussions*

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.